Meeting
2014 ASCO Annual Meeting
Clinical activity and safety of HM61713, an EGFR-mutant selective inhibitor, in advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations who had received EGFR tyrosine kinase inhibitors (TKIs).
Presenter
Dong-Wan Kim, MD, PhD
Seoul National University Hospital
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Clinical Science Symposium
Session Title
Targeting EGFR: The Next 10 Years
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT01588145
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8011)
DOI
10.1200/jco.2014.32.15_suppl.8011
Abstract #
8011
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
REZILIENT2: Phase 2 study of zipalertinib in patients with advanced non-small cell lung cancer (NSCLC) with exon 20 insertions (ex20ins) and other uncommon epidermal growth factor receptor (EGFR) mutations.
Speaker: Helena Alexandra Yu, MD
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
Moderated Panel Discussion with Drs. Feng, Kalyan, Goyal, Meyer, and Villanueva
Speaker: Panel Discussion
Videos & Slides
2014 ASCO Annual Meeting
![Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).](https://d201v5jt9ylckg.cloudfront.net/144/8779/95362/95362_video_pv.jpg)
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).
Speaker: James Chih-Hsin Yang, MD, PhD
Speaker: David P. Ryan, MD